Patient Knowledge of Pharmacogenetic Information Improves Adherence to Statin Therapy: Results of the Additional Kif6 Risk Offers Better Adherence to Statins (Akrobats) Trial

ABCG2 Gene Polymorphisms as Risk Factors for Atorvastatin Adverse Reactions: A Case–Control Study

“…All patients were of Croatian ancestry. Median (interquartile range) age was 56 (48-66) and 60 (53)(54)(55)(56)(57)(58)(59)(60)(61)(62)(63)(64)(65)(66)(67)(68)(69)(70) in the groups of patients with and without ADRs, respectively. The gender distribution was identical, and atorvastatin median prescribed dose was the same in both groups.…”

“…Currently there is no direct clinical evidence that the personalized prescribing of statins using genotyping will improve patients' medication adherence; however, previous analyses suggest that this is a logical conclusion [58]. There is evidence that genomic information could be used as a behavioral health intervention [59] affecting patient's sense of self efficacy while AKROBATS study provides prospective evidence that pharmacogenetic testing has utility in modifying patient adherence [60].…”

Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT)

“…Since its approval by the FDA in 1954, warfarin has become one of the most widely prescribed anticoagulants in the United States. 32,33 Warfarin has been shown to reduce this risk of clinical events in patients with thrombotic diathesis but carries numerous limitations, including narrow therapeutic range, wide interpatient…”

The potential impact of pharmacogenetic testing on medication adherence

“…7, 8 The inherent personal nature of learning of one’s genetic likelihood of having a positive therapeutic response or not having an adverse effect from a medication may increase perceived efficacy/necessity or decrease patient concern, respectively, ultimately improving medication adherence. The act of testing alone may reduce anxiety about the medication, contributing to increased adherence.…”

“…Poor medication adherence is a well-known problem, particularly in patients with chronic conditions, resulting in greater morbidity, mortality, and health care costs 2–5 . Although the potential benefit of PGx testing to improve adherence has been recognized for chronic diseases such as attention-deficit/hyperactivity disorder 6 and diabetes, 7 it is just beginning to be evaluated as an intervention, either alone or in combination with other interventions 8 . Successful implementation of PGx testing into clinical practice, which assists patients and providers with therapy decisions, is consistent with current national goals to improve health care, engage patients, and reduce health care costs.…”